2,577 results on '"Sasaki, Koji"'
Search Results
152. CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia
153. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34)
154. AML-387 Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD)
155. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia
156. AML-285 Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration
157. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
158. ALL-346 Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients
159. Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost?
160. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib
161. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
162. The utility of transarterial embolization and computed tomography for life-threatening spontaneous retroperitoneal hemorrhage
163. Advantages of Intraprocedural Unenhanced CT During Adrenal Venous Sampling to Confirm Accurate Catheterization of the Right Adrenal Vein
164. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
165. 2545: Evaluation of quality assurance method using 3D moving phantom for Synchrony’s lung tumor tracking
166. Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019
167. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
168. AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation
169. MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation
170. MDS-614 Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations
171. POSTER: CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
172. POSTER: CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors
173. POSTER: MDS-208 Characteristics and Outcomes of Patients With Myelodysplastic Syndrome and DDX41 Mutation
174. POSTER: CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
175. CML-573 ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
176. CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
177. CML-487 First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors
178. POSTER: MDS-614 Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations
179. POSTER: AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation
180. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies
181. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia
182. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
183. Supplementary Table 4 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
184. Supplementary Table 5 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
185. FIGURE 2 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
186. Supplementary Figure 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
187. TABLE 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
188. TABLE 2 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
189. Supplementary Table 3 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
190. Supplementary Data Description from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
191. FIGURE 3 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
192. FIGURE 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
193. Supplementary Table 2 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
194. Supplementary Methods from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
195. Supplementary Table 1 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
196. Supplementary Figure 3 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
197. TABLE 3 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
198. FIGURE 4 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
199. Supplementary Table 6 from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
200. Data from Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.